- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04167319
A Feasibility Study Investigating Chemotherapy-induced Neuropathy Using Multi-frequency Tactilometry and Patient-reported Outcomes (PRO) (CINCAN-1)
Chemotherapy induced peripheral neuropathy (CIPN) is among the most feared side effects to cancer treatment. The development of CIPN can lead to discontinuation or omission of antineoplastic drugs, possibly affecting efficacy of cancer treatment. There is a lack of knowledge about the natural course of CIPN and to this date, there are no available methods for the early detection of CIPN. With no effective prevention or treatment options, the condition has severe impact on patient quality of life and healthcare expenditure.
This study will investigate the natural course of paclitaxel- and oxaliplatin induced peripheral neuropathy using novel diagnostic techniques. Multi-frequency vibrational technology has provided an objective method for the early detection of diabetic neuropathy. Our study will test the feasibility of this method within the field of clinical oncology and CIPN.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Roskilde, Danmark, 4000
- Department of Clinical Oncology and Palliative Care
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- ≥ 18 years of age
- A diagnosis of cancer.
- Fulfil the criteria for starting chemotherapy.
- Scheduled to undergo at least 4 courses of paclitaxel- or oxaliplatin-based chemotherapy.
- No prior paclitaxel, oxaliplatin or other neurotoxic chemotherapy.
Exclusion Criteria:
- Unable to complete PRO measures.
- Previous neurotoxic chemotherapy.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Paclitaxel
Patients scheduled to receive paclitaxel as part of their standard treatment
|
We will observe the natural course of CIPN using multiple measurements
|
|
Oxaliplatin
Patients scheduled to receive oxaliplatin as part of their standard treatment
|
We will observe the natural course of CIPN using multiple measurements
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Difference in VPT from baseline to 6 mo.
Tidsram: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in vibrograms from baseline compared to vibrograms after the end of the 6th course of chemotherapy or the last course of chemotherapy (if before course no. 6).
|
through study completion, an average of 1 year and 6 months
|
|
Difference in VPT from Baseline to 4 mo.
Tidsram: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in vibrograms from baseline compared to vibrograms after the end of the 4th course of chemotherapy or the last course of chemotherapy (if before course no.
4).
|
through study completion, an average of 1 year and 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Difference in PRO from baseline and during 1. course chemotherapy.
Tidsram: up to 5 days
|
Difference in the NCCTG-CIPN Questionnaire from baseline compared to 4 days after initiation of chemotherapy course no. 1.
|
up to 5 days
|
|
Difference in VPT from baseline and during 1. course chemotherapy
Tidsram: up to 5 days
|
Difference in the Vibrograms from baseline compared to 4 days after initiation of chemotherapy course no. 1.
|
up to 5 days
|
|
Difference in PRO from baseline to after chemotherapy course no. 3
Tidsram: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in EORTC-QLQ-CIPN20 from baseline compared to after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
|
Difference in PRO from baseline to after chemotherapy course no. 2
Tidsram: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in EORTC-QLQ-CIPN20 from baseline compared to after chemotherapy course no. 2. Some patients receiving oxaliplatin will have 6 courses of planned chemotherapy or planned metastatic treatment, in this case comparison will be made after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
|
Difference in VPT from baseline to af chemotherapy course no. 3
Tidsram: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in the Vibrograms from baseline compared to after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
|
Difference in VPT from baseline to af chemotherapy course no. 2
Tidsram: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in the Vibrograms from baseline compared to after chemotherapy course no. 2. Some patients receiving oxaliplatin will have 6 courses of planned chemotherapy or planned metastatic treatment, in this case comparison will be made after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
|
No. of discontinuations
Tidsram: through study completion, an average of 1 year and 6 months
|
Number of patients not completing their planned courses of chemotherapy (reasons for discontinuation will be registered).
|
through study completion, an average of 1 year and 6 months
|
|
No. of dose reductions
Tidsram: through study completion, an average of 1 year and 6 months
|
Number of patients that need reductions of chemotherapy dose (reasons will be registered)
|
through study completion, an average of 1 year and 6 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- REG-088-2019
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .